References


[Acupuncture to relieve urinary pyelonephritis symptoms in elderly patients] - PubMed Central (PMC)


Selective immunoadsorption for neurological diseases with easy to handle single use column

**Indication**

**Autoimmune diseases**
(e.g., Myasthenia gravis (MG), Guillain-Barré syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy (CIDP), Multiple sclerosis (MS), Neuromyelitis optica (NMO)/ Neuromyelitis optica spectrum disorders (NMOSD), NMDA receptor antibody/ VGKC antibody encephalitis)

**Features of IMMUSORBA TR-350(L)**
- Therapeutic plasmapheresis by removing pathogenic substances (anti-acetylcholine receptor antibodies and immune complexes) from patient's plasma by selective adsorption.
- No need for the replacement of plasma, minimizing the risk of infection with hepatitis, AIDS, etc.
- Applicable to patients with protein allergy.

**Clinical Course**

**Efficacy of immunoadsorption for patient with Myasthenia gravis (MG)**

Mean values of myasthenia gravis score and titer of ACHR antibodies in the 11 improved patients after immunoadsorption therapy. Consecutive immunoadsorption treatments induced a significant fall of the myasthenia gravis score and a decrease in the titer of ACHR antibodies. The myasthenia gravis score remained low even on day 42 despite the rise in ACHR antibody titer.

**Specifications**

**Adsortion Column**
- **Material**: Trypsin-antibody-immobilized polyvinyl alcohol gel
- **Volume**: 350mL
- **Container**: Polypropylene
- **Weight**: 550g
- **Sterilization**: Mastisol

**Microparticle Removal Filter**
- **Material**: Polyethylene (coated with ethylene-vinyl alcohol copolymer)
- **Volume**: 350mL
- **Container**: Poly (vinyl chloride)
- **Sterilization**: Ethylene oxide

**Caution**

For patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitor, there is a possibility that treatment with the IMMUSORBA TR-350(L) will lead to a drop in blood pressure. Simultaneous treatment with ACE inhibitor and the IMMUSORBA TR-350(L) must be avoided.

The IMMUSORBA TR-350(L) is intended for the treatment of plasma. Never run whole blood through the IMMUSORBA TR-350(L) and may cause blockage. Do not use the IMMUSORBA TR-350(L) with plasma containing a large amount of thrombocytes.
Selective immunoadsorption for neurological diseases with easy to handle single use column

**Indication**

Autoimmune diseases (e.g., Myasthenia gravis (MG), Guillain-Barré syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy (CIDP), Multiple sclerosis (MS), Neuromyelitis optica (NMO)/Neuromyelitis optica spectrum disorders (NMOSD), NMDA receptor antibody/VGKC antibody encephalitis)

**Features of IMMUSORBA TR-350(L)**

- Therapeutic plasmapheresis by removing pathogenic substances (anti-acetylcholine receptor antibodies and immune complexes) from patient’s plasma by selective adsorption.
- No need for the replacement of plasma, minimizing the risk of infection with hepatitis, AIDS, etc.
- Applicable to patients with protein allergy.

**Clinical Course**

- **Efficacy of immunoadsorption for patient with Myasthenia gravis (MG)**

Mean values of myasthenia gravis score and titer of AChR antibodies in the 11 improved patients after immunoadsorption therapy. Consecutive immunoadsorption treatments induced a significant fall of the myasthenia gravis score and a decrease in the titer of AChR antibodies. The myasthenia gravis score remained low even on day 42 despite the rise in AChR antibody titers.

**Circuit Diagram**

**Specifications**

- **Adsorption Column**
  - Material: Trypsinoham immobilized polyvinylalcohol gel
  - Volume: 500mL
  - Container: Polyethylene
  - Weight: 650g
  - Sterilization: Ethylene oxide

- **Filter**
  - Material: Polyethylene (coated with ethylene-vinylcarboxylic copolymer)
  - Container: Polyvinylchloride
  - Weight: 5cm

**Caution**

For patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitor, there is a possibility that treatment with the IMMUSORBA TR-350(L) will lead to a drop in blood pressure. Simultaneous treatment with ACE inhibitor and the IMMUSORBA TR-350(L) must be avoided.

The IMMUSORBA TR-350(L) is intended for the treatment of plasma. Never run whole blood through the IMMUSORBA TR-350(L) and may cause blockage. Do not use the IMMUSORBA TR-350(L) with plasma containing a large amount of thrombocytes.
References


